Summary Glutathione S-transferase (GST) isoenzyme composition, isoenzyme quantities and enzymatic activity were investigated in benign (n = 4) ovarian tumours and malignant ovarian tumours, before (n = 20) and after (n = 16) chemotherapy. Enzymatic activity of GST in cytosols was measured by determining 1-chloro-2,4-dinitrobenzene conjugation with glutathione, cytosolic GST subunits were determined by wide pore reversed phase HPLC, using a S-hexylglutathione-agarose affinity column, and isoelectric focussing. Both GST activity and GST pi amount were not related to histopathologic type, differentiation grade, or tumour volume index in untreated malignant tumours. GST isoenzyme patterns were identical in benign tumours and malignant tumours before and after platinum/cyclophosphamide chemotherapy, while GST pi was the predominant transferase. Mean GST activity and GST pi amount were decreased (P < 0.05) in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy compared to untreated ovarian malignant tumours. No relation was found in untreated ovarian tumours between GST pi amount and response to platinum/cyclophosphamide chemotherapy. Thus, within the limitations of the current study no arguments were found for a role of GST in in vivo drug resistance of malignant ovarian tumours to platinum/ cyclophosphamide chemotherapy.
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Ovarian cancer is the fourth most frequent cause of cancer death in women and the gynaecological cancer with the highest mortality (Piver et al., 1991) . The primary scheme for the treatment of patients with advanced ovarian carcinoma consists nowadays of cytoreductive surgery followed by systemic chemotherapy with platinum and cyclophosphamide containing combination regimens (Ozols & Young, 1991) . Despite response rates of 50-80% to chemotherapy the above scheme results in only 15 to 20% long term survivors (Thigpen et al., 1989; Ozols & Young, 1991) . These clinical data indicate, that in ovarian cancer intrinsic and acquired drug resistance occurs to platinum and cyclophosphamide containing regimens. In cell lines numerous mechanisms that can contribute to resistance to cisplatin have been identified, such as changes in membrane permeability, the ability to remove cytotoxic lesions from DNA, and changes in detoxification pathways (Andrews & Howell, 1990) . With regard to cyclophosphamide and other anticancer drugs of the alkylating class, numerous studies point to the likelihood that changes in GST isoenzyme composition and quantity contribute in an important way to the resistance of tumour cells (Waxman, 1990) .
The aim of this study was to identify and quantify GST isoenzymes in benign and malignant tumours of the ovary, before and after chemotherapy and to relate the levels of these enzymes in untreated tumours to response of these tumours to chemotherapy. GSTs are a family of multifunctional cytosolic proteins that function as important enzymes of detoxification by catalyzing the conjugation of electrophilic compounds to glutathione, and the non-covalent binding of various lipophilic compounds (Boyer, 1989) . In man, cytosolic GSTs have been divided into four major classes termed alpha (basic), mu (neutral), pi (acidic) and theta (Mannervik et al., 1985; Ogura et al., 1991) . As these isoenzymes are known to have different substrate specifities, both the total GST activity and the isoenyzme composition may be important determinations of a tumours' ability to detoxify different chemotherapeutic agents (Mannervik & Danielson, 1988) . In numerous human tumour cell lines resistant to cisplatin an enhanced GST content has been described, as well as in human tumour cell lines resistant to alkylating agents (for a review, see Meyer et al., 1990a; Teicher et al., 1991; Ali-Osman et al., 1990; Ford et al., 1991) . However, almost no data are available on GST activity and isoenzyme expression in tumours in vivo. In order to determine a possible role of GSTs in de novo and acquired resistance to platinum/cyclophosphamide chemotherapy we measured in this study the enzymatic activity, subunit composition and tissue concentration of GSTs in benign ovarian tumours, malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. The relation between GST content of the untreated malignant tumours with histopathologic type, differentiation grade and tumour volume index, as well as the relation between the GST content of the malignant ovarian tumours with the clinical response to chemotherapy was investigated.
Materials and methods
Human materials Tumour specimens were obtained from patients operated at cooperating hospitals in the northern part of the Netherlands during the period 1989-1991. Tumour collection was supervised by a pathologist. After dissection samples were immediately frozen in liquid nitrogen and stored at -180°C until further analysis. In two patients, tumour specimens were obtained at first laparotomy and at second look operation after chemotherapy. In one untreated patient with ovarian cancer tumour specimens were obtained from the left and right ovarian tumour. In two patients four, and in two patients three specimens from different sites of the same tumour were obtained.
Pathological characteristics
The tumours were histologically classified according to the World Health Organisation classification using paraffin embedded tissue sections (Serov et al., 1973) . One section per cm tumour diameter was made to get a good overall impression of the tumour histology. Carcinomas were graded into well, moderately, and poorly differentiated (Sobre et al., 1982) . Tumour HPLC separation and quantification of GST subunits and determination of GST activity All actions were performed at 4°C, unless specified. All tumours' aliquots (weights ranging from 37-650 mg) were homogenised in 3.0 ml of Tris/HCI (25 mM, pH 7.4), using an ultra-turrax. To avoid contamination by connective tissue, the epithelium of the cystadenomas was dissected away from the cyst wall and used for further analysis. Cytosols were prepared by 90 min centrifugation at 110,000g. Cytosolic GST was purified as described previously (Bogaards et al., 1989) . In brief a fixed amount of cytosol was applied to a 2 ml S-hexylgluthathione-agarose affinity column, washed with 16 ml buffer containing 0.4 M NaCl, and eluted in the same buffer containing 5 mM of S-hexylglutathione. The eluates preceding the S-hexylglutathione alpha eluate were checked for GST activity, and usually contained less than 5% of the total applied enzymatic activity. The eluate was concentrated to approximately 0.2 ml, using a centricon PM 10 ultrafiltration tube (Amicon, Danvers, USA), and 100 gLI was applied to wide pore reversed phase HPLC (Vydac 105 TP 250 x 4.3 mm column). The subunits were eluted with a gradient of acetonitrile in water, both containing 0.1% trifluoroacetic acid (from 40 to 50% acetonitrile in 18 min, followed by a further increase to 53% in 5 min and isocrating elution for another 7 min). Detection was at 214 nm, while peak integration was performed using Nelson analytical software. Concerning the method of quantification, it should be noted that possible theta class isoenzymes present in tumour tissues are not observed using this method, since they do not bind to the affinity matrix and show almost no enzymatic activity towards 1-chloro-2,4-dinitrobenzene (CDNB).
Human GST isoenzymes used for reference and quantification purposes was purified from a human placenta by means of S-hexylglutathione affinity chromatography and chormatofocusing, as described previously (van Ommen et al., 1990) . For isoelectric focusing, a Pharmacia Phastsystem was used (pH range 3-9 precoates). Enzymatic activity of GST (conjugation of CDNB with glutathione) was performed according to Habig (Habig et al., 1974 GST pi/differentiation grade malignant ovarian tumours
Identification of GST subunits
Reversed phase HPLC separation of the affinity column eluate showed the subunit pi to be the predominant transferase present in all samples (Figure 3, lower panel) . This was confirmed both by comparison with HPLC chromatograms of known mixtures of human liver GST (Figure 3 , upper panel), comparison with purified GST pi isoenzymes and by co-elution of tumour transferases with purified GST pi. Isoelectric focussing of the purified tumour GST isoenzyme mixture, together with purified GST pi confirmed the acidic nature of the predominant tumour GST (results not shown). A minor subunit ( < 3% of total cytosolic GST) was detected in most samples (Figure 3) . Although not completely characterised, the corresponding isoenzyme has a molecular weight of ca. 27,000 dalton and a pl of 5.1. It possesses a rather low specific activity towards CDNB (ca. 5 U mg-1). We have also observed this subunit in human liver and placenta (results not shown).
No differences in subunit composition were observed either within the benign and malignant tumours, or between the malignant tumours before and after chemotherapy. mean GST activity in benign tumours and mean GST activity in residual or recurrent tumours after chemotherapy. In the four patients from whom tumour specimens were obtained from respectively three and four different sites of the tumours the variation within these tumours was relatively small. The specific activity measured in cytosols in the different specimens always showed a standard deviation of less than 18%, both for untreated tumours, and tumours after chemotherapy. In one of the two patients from who Relation between activity and subunit composition Figure 4 presents the relation between the cytosolic GST activity (CDNB conjugation) and the amount of GST (Figure 1 , 2, and 5). Tumours after chemotherapy were not included to rule out possible influence of chemotherapy on GST pi amount.
GST pi amount and response to chemotherapy Table III shows the amount of GST pi mg-' cp, FIGO stage, chemotherapeutic regimen, and response to chemotherapy in 20 patients in which GST pi was measured in tumour specimens before treatment. Two of these patients did not receive chemotherapy because of FIGO stage I, one patient was considered too old, and three patients received monotherapy because of high age. In two of the patients with PD during first line chemotherapy a second look laparotomy was performed to make another effort for debulking the tumour load. Figure 6 presents the relation between the GST pi amount mg-' cp and response to platinum/cyclophosphamide chemotherapy. No rank correlation was found. In the group of eight patients with residual disease, from which tumours were obtained after chemotherapy, progressive disease occurred in all patients despite second and sometimes third line chemotherapy (various regimens). In the group of eight patients with recurrent disease after first line chemotherapy progressive disease occurred in five patients during second line chemotherapy (various regimens), one patient was lost for follow-up, and complete remission after second line chemotherapy occurred in two patients (one patient received six courses of methotrexate, and one patient six courses of cisplatin/cyclophosphamide). Recurrence of disease after first line chemotherapy in these last two patients occurred after 4 and 5 years, respectively. In the patients with residual or recurrent disease no relation was found between GST pi levels in the tumour specimens and response to second line chemotherapy.
Discussion
Response to platinum/cyclophosphamide chemotherapy in ovarian cancer is quite variable. Well known prognostic factors in ovarian cancer are FIGO stage, differentiation grade, age of the patient, histopathologic type, residual tumour load after first laparotomy, morphometrical features and cellular DNA content (Baak et al., 1988) . However, even within a group of patients with the same prognostic factors the response to chemotherapy is unpredictable. Therefore additional markers are needed to predict response to chemotherapy. Recently, a positive correlation between the enzymatic activity of GST and drug resistance to platinum and/or alkylating agents has been reported in cell lines Meyer et al., 1990a; Teicher et al., 1991; Ali-Osman et al., 1990; Ford et al., 1991) . Cell lines with in vitro acquired resistance or cell lines derived from resistant tumours showed higher GST levels than their non-resistant equivalents. Furthermore, expression of GST genes in cell lines led to a resistance against these types of compounds (Moscow et al., 1989a) . These observations suggest a role of GST in acquired drug resistance, possibly by means of an increased glutathione conjugation of antineoplastic agents or their reactive intermediates. Repeated treatment of patients with malignant ovarian tumours with platinum and/or alkylating agents may induce overexpression of GST. In this study both GST enzymatic activity and GST pi (which was the dominant GST isoenzyme) level were lower after treatment with platinum/cyclophosphamide in comparison to untreated tumours. However, as in most in vivo studies, also our study is characterised by several complicating factors. Even in the patients with residual disease after chemotherapy the period between last course of chemotherapy and time of excision of the tumour specimen was at least 4 weeks, and therefore a possible transient rise in GST levels may be missed. Our series is small, and the range of histological types of tumours is wide. In only two patients tumour specimens were obtained before and after chemotherapy. GST pi levels were lower after chemotherapy in these two patients with paired specimens, while in one patient GST activity was lower, and in the other GST activity was higher after chemotherapy. Lower GST activity in malignant ovarian tumours after chemotherapy is in agreement with the findings of Djuric et al. who found decreased activity of GST in malignant ovarian tumours after platinum/cyclophosphamide chemotherapy (Djuric et al., 1990) . In their study isoenzyme patterns of GSTs, and relations of GST pi level to response to chemotherapy were not determined.
In this study the acidic pi class GST was the most abundant GST form in benign ovarian tumours, and in malignant ovarian tumours, as was found by others in different human tumours, including lung, colon, bladder, and breast tumours (Di Ilio et al., 1985; Carmichael et al., 1988; Shea et al., 1988; 1990) . Lewis et al. (1989) , 1991 ). In the current study no relation could be found between GST pi levels in untreated malignant ovarian tumours and response of these patients to platinum/cyclophosphamide chemotherapy. So far no further data exist in literature on GST pi levels in tumours and response to platinum/cyclophosphamide chemotherapy. In patients with human breast tumours no relation was found between GST pi expression and in vitro chemosensitivity to doxorubicin (Keith et al., 1990) , and in another study in human breast tumours no relation was found between GST pi content and other prognostic factors (Shea et al., 1990) . Kim et al. also did not find GST pi expression as an indicator of response to adriamycin in 15 human tumours (Kim et al., 1991) . Lower levels of GST pi after platinum/cyclophosphamide chemotherapy and no relation of GST pi levels with response to platinum/cyclophosphamide chemotherapy both do not suggest an important role of GST pi in in vivo drug resistance. However, for the assays, as used in our study, homogenisation of tissue is required. In this way small subpopulations of tumour cells with high GST pi levels between large populations of tumour cells with low GST pi levels can be missed. Terrier et al. found heterogeneity of expression of GST pi among different normal human tissues and also heterogeneity of GST pi expression within the same tissue using an immunohistochemical detection technique (Terrier et al., 1990) . Recently Rahilly et al. also found heterogeneity of GST isoenzyme expression in benign and untreated malignant ovarian tumours (Rahilly et al., 1991) . Perhaps the small subpopulations with high GST pi levels will eventually determine the response of the tumour to chemotherapy, and therefore, although not in favour for a significant role for GST pi as marker of clinical drug resistance, out study does not rule out a possible role of GST isoenzymes in clinical drug resistance. In the future determination of GST pi levels with HPLC as well as an indirect immunohistochemical technique, using a polyclonal antibody against GST pi, can elucidate this problem. Another complicating factor in evaluating GST and glutathione levels in tumour specimens is the fact, that GSTs and glutathione are parts of a complicated detoxification system, of which glutathione and GSTs steady states are often used to deter-mine the level of this detoxification system, as was done for GSTs in the current study. Insight in the kinetics of glutathione and GST status should give a more dynamic representation of the continuous availability of this defence (Meijer et al., 1990b) . However, our findings, that GST pi levels in untreated tumours showed no relation to response to chemotherapy, and that GST pi levels were decreased in malignant tumours after platinum/cyclophosphamide chemotherapy make the eventual use in clinical trials of inhibitors of GST enzymes, such as ethacrynic acid or piriprost as modulation strategy in enhancing sensitivity of malignant tumours to platinum/cyclophosphamide chemotherapy not very promising (Schilder et al., 1990) . Our study indicates that other in vitro well established mechanisms of drug resistance, such as decreased cell membrane transport of platinum, other detoxification pathways, and changes in repair of platinum DNA adducts, need to be evaluated in vivo, as was done for GSTs in the present study.
